Pasithea Therapeutics (KTTA) vs Shuttle Pharmaceuticals (SHPH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Pasithea Therapeutics (KTTA) has outperformed Shuttle Pharmaceuticals (SHPH) over the past year, gaining 63.9% versus a loss of 78.2%. Pasithea Therapeutics is the larger company by market cap ($17.6 million vs $16.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KTTA | SHPH |
|---|---|---|
| Share price | $0.4787 | $3.49 |
| Market cap | $17.59M | $16.63M |
| 1-day change | -0.48% | -10.51% |
| YTD return | -62.89% | -80.61% |
| 1-year return | +63.94% | -78.19% |
| 5-year return | -99.40% | — |
| EPS (TTM) | $-1.38 | $-16.87 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-20.43M | $-11.72M |
| 52-week high | $2.06 | $44.40 |
| 52-week low | $0.32 | $2.58 |
| Distance from 52-week high | -76.76% | -92.14% |
| Analyst consensus | none | — |
| Avg. price target upside | +526.70% | — |
| Average volume | 705.64K | 41.80K |
| Shares outstanding | 36.75M | 4.76M |
| Employees | 5 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KTTA has outperformed SHPH by 142.1 percentage points over the past year.
About Pasithea Therapeutics
KTTA stock →Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
About Shuttle Pharmaceuticals
SHPH stock →Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to treat cancers. It owns a pharmaceutical software artificial intelligence (AI) driven platform for molecular discovery and early-stage drug development.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
KTTA vs SHPH FAQ
Which is bigger, Pasithea Therapeutics or Shuttle Pharmaceuticals?
Pasithea Therapeutics (KTTA) is larger, with a market capitalization of $17.59M compared with $16.63M for Shuttle Pharmaceuticals (SHPH).
Which stock has performed better over the past year, KTTA or SHPH?
KTTA returned +63.94% over the past 12 months, compared with -78.19% for SHPH (price return, excluding dividends). Past performance does not predict future results.
Are Pasithea Therapeutics and Shuttle Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.